|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
63,980,000 |
Market
Cap: |
588.62(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$8.22 - $11.59 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 245 |
Guru Rank Value : 4.8 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
1,254 |
5,114 |
22,963 |
172,089 |
Total Sell Value |
$10,922 |
$50,468 |
$231,475 |
$1,835,193 |
Total People Sold |
1 |
2 |
2 |
4 |
Total Sell Transactions |
1 |
3 |
11 |
21 |
End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Samaha Eli |
10% Owner |
|
2022-09-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,012,226 |
|
4% |
|
Wam Gp Llc |
10% Owner |
|
2022-09-19 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,457,060 |
|
6% |
|
Glaxosmithkline Plc |
Former 10% Owner |
|
2022-09-16 |
4 |
D |
$9.75 |
$94,036,868 |
I/I |
(9,644,807) |
0 |
|
- |
|
Hindman Andrew A. |
SVP, CHIEF FINANCIAL OFFICER |
|
2022-08-19 |
4 |
D |
$9.34 |
$239,814 |
D/D |
(25,676) |
473,507 |
|
- |
|
Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
|
2022-08-19 |
4 |
D |
$9.34 |
$147,609 |
D/D |
(15,804) |
1,424,784 |
|
- |
|
Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
|
2022-08-19 |
4 |
D |
$9.34 |
$97,257 |
D/D |
(10,413) |
319,577 |
|
- |
|
Graham Richard A |
SVP, DEVELOPMENT |
|
2022-08-19 |
4 |
D |
$9.34 |
$177,376 |
D/D |
(18,991) |
345,754 |
|
- |
|
Graham Richard A |
SVP, DEVELOPMENT |
|
2022-08-16 |
4 |
S |
$9.71 |
$47,640 |
D/D |
(4,906) |
364,745 |
|
-14% |
|
Graham Richard A |
SVP, DEVELOPMENT |
|
2022-08-09 |
4 |
S |
$8.79 |
$132,606 |
D/D |
(15,086) |
369,651 |
|
-20% |
|
Hindman Andrew A. |
SVP, CHIEF FINANCIAL OFFICER |
|
2022-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
499,183 |
|
- |
|
Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
|
2022-05-23 |
4 |
AS |
$8.93 |
$9,653 |
D/D |
(1,081) |
329,990 |
|
7% |
|
Graham Richard A |
SVP, DEVELOPMENT |
|
2022-05-20 |
4 |
D |
$8.74 |
$34,497 |
D/D |
(3,947) |
384,737 |
|
- |
|
Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
|
2022-05-20 |
4 |
D |
$8.74 |
$19,228 |
D/D |
(2,200) |
331,071 |
|
- |
|
Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
|
2022-05-20 |
4 |
D |
$8.74 |
$96,359 |
D/D |
(11,025) |
1,440,588 |
|
- |
|
Hindman Andrew A. |
SVP, CHIEF FINANCIAL OFFICER |
|
2022-05-20 |
4 |
D |
$8.74 |
$29,410 |
D/D |
(3,365) |
479,183 |
|
- |
|
Pakianathan Deepika |
|
|
2022-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
9,852 |
27,747 |
|
- |
|
Young William D |
|
|
2022-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
9,852 |
78,010 |
|
- |
|
Mitchell Dean J |
|
|
2022-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
9,852 |
60,886 |
|
- |
|
Oconnor Donal |
|
|
2022-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
9,852 |
53,886 |
|
- |
|
Malkiel Burton G |
|
|
2022-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
9,852 |
91,457 |
|
- |
|
Smaldone Alsup Laurie |
|
|
2022-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
9,852 |
44,662 |
|
- |
|
Broshy Eran |
|
|
2022-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
9,852 |
60,886 |
|
- |
|
Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
|
2022-02-28 |
4 |
AS |
$10.16 |
$23,947 |
D/D |
(2,356) |
333,271 |
|
-8% |
|
Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
|
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
170,000 |
1,449,300 |
|
- |
|
Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
|
2022-02-18 |
4 |
D |
$9.61 |
$218,243 |
D/D |
(22,710) |
1,279,300 |
|
- |
|
94 Records found
|
|
Page 1 of 4 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|